AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 292 min read$CGC

Lazzarato David Angelo sold $21K of CGC

Lazzarato David Angelo sold 22,674 shares of Canopy Growth Corp (CGC) at $0.92 on 2026-06-26.

Original reporting
SEC EDGAR · Lazzarato David Angelo
Published Jun 29, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CGC
Neutral
medium confidence
Mentioned
$CGC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

A director’s open-market sale of 22,674 shares at $0.9237/share is disclosed; the filing does not include any new operational or financial guidance.

02

Market read

Traders may note insider selling, but the transaction size (~$21k) and lack of accompanying fundamental news make it unlikely to drive a major repricing.

03

What to watch

Insider sales can be driven by diversification, taxes, or personal liquidity needs; without additional context (e.g., other insiders selling/buying, changes in compensation), the signal is weak.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-29 after-hours; reflects sale executed 2026-06-26.

Background

The article is an SEC Form 4 insider transaction for Canopy Growth Corp (CGC), reported via SEC EDGAR.

Company-level read

Ticker impact

$CGCNeutralMedium confidence
Context

SEC Form 4 shows director Lazzarato David Angelo sold 22,674 CGC shares on 2026-06-26 at $0.9237/share.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any impact is likely short-lived.

Evidence & confidence

The filing discloses a single insider sale size (~$21k) with no 10b5-1 plan, but it is not accompanied by new company fundamentals, guidance, or material corporate action.

Market effects

Sector

No sector read-across; this is an isolated insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale was not under a 10b5-1 plan, some traders may interpret it as a stronger near-term caution signal than a scheduled plan—though the dollar value is small.

Key entities

  • issuer
    Canopy Growth Corp

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Lazzarato David Angelo

    Director who sold 22,674 shares on 2026-06-26.

Read at source← All news

Related articles

AUG 7
$CGCMed

Canopy Growth Q1 Earnings Call Highlights

Canopy Growth (NASDAQ:CGC) reported Q1 Canadian adult-use revenue up 10% to C$29.7 million and international revenue up 10% year over year, citing growth in Poland. Adjusted consolidated gross margin rose to 31% from 25% a year earlier. Storz & Bickel revenue rose 6% to C$16.1 million. Canopy said it expects UK flower shipments to start imminently, with revenue in 2H FY2027.

yahoo.com6 min
AUG 7
$CGCMedAI 8/10

Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses

Canopy Growth (TSX: WEED, Nasdaq: CGC) reported Q1 FY2027 results for the three months ended June 30, 2026. Consolidated net revenue rose 13% to C$81.2M, with growth across Canada medical, Canada adult-use, and international. Adjusted gross margin increased to 31% and the adjusted EBITDA loss narrowed 59% to C$3.2M. Free cash outflow widened to C$25.7M.

montrealgazette.com6 min
AUG 7
$CGCMed

Canopy Growth Corp (CGC): Results of Operations and Financial Condition

Canopy Growth Corp (CGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cgc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses Net revenue growth of 22% in Canada medical cannabis, 10% in Canada adult-use canna

SEC EDGAR 8-K6 min
JUN 15
$CGCMed

Cannabis Catalysts: Canopy Growth's FY2026 Revenue Climbs as High Tide Adds Four Ontario Stores

Canopy Growth reported Q4 FY2026 net revenue of C$71.2 million (+10% YoY) and full-year revenue of C$284.6 million (+6%). Canada medical revenue rose 27% to C$25.3 million and international revenue rose 68% to C$8.6 million. Canopy ended FY2026 with C$131.3 million net cash and expects positive Adjusted EBITDA in FY2027. High Tide agreed to buy four Ontario stores for C$7.74 million, adding to 228 Canna Cabana locations in Canada and 103 in Ontario, pending TSXV and AGCO approvals.

investorideas.com6 min
JUN 15
$CGCMed

Canopy Growth Corp (CGC): Results of Operations and Financial Condition

Canopy Growth Corp (CGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cgc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis Full-year 2026 growth driven by net revenue

SEC EDGAR 8-K6 min